62
Participants
Start Date
May 9, 2024
Primary Completion Date
February 28, 2026
Study Completion Date
August 31, 2027
quaratusugene ozeplasmid
Quaratusugene ozeplasmid is an experimental nonviral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.
atezolizumab
Atezolizumab is a monoclonal antibody that belongs to a class of drugs that binds to the programmed death-receptor 1 ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions.
RECRUITING
Virginia Cancer Specialists, PC, Fairfax
RECRUITING
Gabrail Cancer Center Research, Canton
RECRUITING
Oncology_Hematology Care Clinical Trials, LLC, Fairfield
RECRUITING
Oncology_Hematology Care Clinical Trials, LLC, Cincinnati
RECRUITING
Oncology_Hematology Care Clinical Trials, LLC, Cincinnati
RECRUITING
Oncology_Hematology Care Clinical Trials, LLC, Cincinnati
RECRUITING
Oncology_Hematology Care Clinical Trials, LLC, Cincinnati
RECRUITING
Washington University School of Medicine - Siteman Cancer Center, St Louis
RECRUITING
Texas Oncology - DFW, Dallas
RECRUITING
Texas Oncology - Northeast Texas, Tyler
RECRUITING
Rocky Mountain Cancer Centers, LLP, Lone Tree
RECRUITING
Providence Cancer Institute, Portland
RECRUITING
Northwest Cancer Specialists, P.C., Tigard
RECRUITING
Northwest Cancer Specialists, P.C., Portland
RECRUITING
Willamette Valley Cancer Institute (Oregon), Eugene
TERMINATED
Northwest Cancer Specialists, P.C., Vancouver
RECRUITING
Northwest Cancer Specialists, P.C., Portland
Lead Sponsor
Genprex, Inc.
INDUSTRY